{
    "name": "etelcalcetide",
    "comment": "Rx",
    "other_names": [
        "Parsabiv"
    ],
    "classes": [
        "Calcium-Sensing Receptor Agonists"
    ],
    "source": "https://reference.medscape.com/drug/parsabiv-etalcalcetide-1000092",
    "pregnancy": {
        "common": [
            "There are no available data on the use in pregnant women"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In animal reproduction studies, effects were seen at doses associated with maternal toxicity that included hypocalcemia",
                    "In a prenatal and postnatal study in rats administered etelcalcetide during organogenesis through delivery and weaning, there was a slight increase in perinatal pup mortality, delay in parturition, and transient effects on pup growth at exposures 1.8 times the human exposure for the clinical dose of 15 mg 3 times/week"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Studies in rats showed distribution in milk at concentrations similar to plasma",
            "Because of the potential for etelcalcetide to cause adverse effects in breastfed infants, including hypocalcemia, use is not recommended while breastfeeding"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to etelcalcetide or any of its excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Cases of hypotension, congestive heart failure, and decreased myocardial performance reported in clinical trials; reductions in corrected serum calcium may be associated with congestive heart failure, however, a causal relationship could not be completely excluded closely monitor for worsening signs and symptoms of heart failure",
                "Adynamic bone may develop if PTH levels are chronically suppressed; if PTH levels decrease below the recommended target range, the dose of vitamin D sterols and/or etelcalcetide should be reduced or discontinued; after discontinuation, resume therapy at a lower dose to maintain PTH levels in the target range",
                "Rare reports of upper GI bleeding occurred during clinical trials; the exact cause of the GI bleeds were unknown and there were too few cases to determine if GI bleeding was related to this medication; patients with risk factors for upper GI bleeding (such as known gastritis, esophagitis, ulcers, or severe vomiting) may be at increased risk for GI bleeding while receiving therapy; monitor patients for worsening of common GI adverse reactions of nausea and vomiting associated with this medication and for signs and symptoms of GI bleeding and ulcerations during therapy; promptly evaluate and treat any suspected GI bleeding"
            ],
            "specific": [
                {
                    "type": "Hypocalcemia",
                    "description": [
                        "Etelcalcetide lowers serum calcium and can lead to hypocalcemia, sometimes severe; low serum calcium can cause paresthesias, myalgias, muscle spasms, seizures, QT interval prolongation, and ventricular arrhythmia",
                        "Coadministration with another oral calcium-sensing receptor agonist could result in severe, life-threatening hypocalcemia; closely monitor corrected serum calcium in patients receiving etelcalcetide and concomitant therapies known to lower serum calcium",
                        "Patients with congenital long QT syndrome, history of QT interval prolongation, family history of long QT syndrome or sudden cardiac death, and other conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk for QT interval prolongation and ventricular arrhythmias if they develop hypocalcemia due to therapy; closely monitor corrected serum calcium and QT interval in patients at risk receiving therapy",
                        "Significant reductions in corrected serum calcium may lower threshold for seizures; patients with a history of seizure disorder may be at increased risk for seizures if they develop hypocalcemia due to this medication; monitor corrected serum calcium in patients with seizure disorders receiving therapy",
                        "Do not initiate in patients if corrected serum calcium is less than lower limit of normal; monitor corrected serum calcium within 1 week after initiation or dose adjustment and every 4 weeks during treatment; educate patients on symptoms of hypocalcemia and advise them to contact a healthcare provider if they occur",
                        "If corrected serum calcium falls below lower limit of normal or symptoms of hypocalcemia develop, start or increase calcium supplementation (including calcium, calcium-containing phosphate binders, and/or vitamin D sterols or increases in dialysate calcium concentration); dose reduction or discontinuation of therapy may be necessary"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cinacalcet",
            "description": {
                "common": "cinacalcet, etelcalcetide.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Discontinue cinacalcet for at least 7 days before starting etelcalcetide. Concurrent administration of CaSR agonists could result in severe, life-threatening, hypocalcemia."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Decreased serum calcium",
            "percent": "7.5"
        },
        {
            "name": "asymptomatic reductions in calcium",
            "percent": "7.5"
        },
        {
            "name": "mg",
            "percent": "8.3"
        },
        {
            "name": "dL or clinically significant asymptomatic reductions in corrected serum calcium between",
            "percent": "64"
        },
        {
            "name": "and",
            "percent": "12"
        },
        {
            "name": "mg",
            "percent": "11"
        },
        {
            "name": "dL that required medical management",
            "percent": "11"
        },
        {
            "name": "Muscle spasms",
            "percent": "9"
        },
        {
            "name": "Diarrhea",
            "percent": "8"
        },
        {
            "name": "Nausea",
            "percent": "7"
        },
        {
            "name": "Vomiting",
            "percent": "6"
        },
        {
            "name": "Headache",
            "percent": "4.4"
        },
        {
            "name": "Hypocalcemia",
            "percent": "4"
        },
        {
            "name": "Paresthesia",
            "percent": "2"
        },
        {
            "name": "Hypersensitivity",
            "percent": "2"
        },
        {
            "name": "Hyperkalemia",
            "percent": "1.2"
        },
        {
            "name": "Hospitalization for heart failure",
            "percent": "1"
        },
        {
            "name": "Myalgia",
            "percent": "8.3"
        },
        {
            "name": "QTc prolongation secondary to hypocalcemia",
            "percent": "0.2"
        },
        {
            "name": "Hypophosphatemia",
            "percent": null
        },
        {
            "name": "Hypocalcemia",
            "percent": null
        },
        {
            "name": "symptomatic reductions in corrected serum calcium",
            "percent": null
        },
        {
            "name": "mg",
            "percent": null
        },
        {
            "name": "dL",
            "percent": null
        },
        {
            "name": "Anaphylactic reaction",
            "percent": null
        },
        {
            "name": "Seizures secondary to hypocalcemia",
            "percent": null
        }
    ]
}